Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 18/20 | 0.48 |
| ▸ | HTR3A | P46098 | 10/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16858320 | 0.97 | HTR4 (0.51) | HTR4HTR3A | |
| Fumaric Acid SCHEMBL16827119 | 0.95 | HTR4 (0.44) | HTR4HTR3AFLT3TYRO3MERTK | |
| Fumaric Acid SCHEMBL16827121 | 0.95 | HTR4 (0.44) | HTR4HTR3AFLT3TYRO3MERTK | |
| Fumaric Acid SCHEMBL16827057 | 0.92 | HTR4 (0.47) | HTR4HTR3A | |
| Fumaric Acid SCHEMBL16827056 | 0.92 | HTR4 (0.47) | HTR4HTR3A | |
| SCHEMBL18171071 | 0.87 | HTR4 (0.58) | HTR4HTR3A | |
| SCHEMBL20078603 | 0.84 | HTR4 (0.42) | HTR4HTR3AFLT3TYRO3MERTK | |
| SCHEMBL16827109 | 0.83 | HTR4 (0.55) | HTR4HTR3A | |
| SCHEMBL16827162 | 0.83 | HTR4 (0.51) | HTR4HTR3A | |
| SCHEMBL18171054 | 0.82 | HTR4 (0.54) | HTR4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105873920-B | As 5-HT4The indazole compound of receptor stimulating agent | 苏文生命科学有限公司 | 2018-06-08 | — | — | CN | claimed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | claimed |
| EP-3099675-B1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-02-14 | — | — | EP | claimed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | claimed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | HTR4 1/4885HTR3A 5/4885FLT3 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.